Lido Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Lido Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,100	Closed	-$363K	–	654
2019 Q3	$363K	Buy	+10,100	New	+$306K	0.02%	408

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lido Advisors's ACAD Position: Q4 2019 in Review

Lido Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q4 2019, closing a stake of 10,100 shares — an estimated $363K sold.

Lido Advisors first reported a position in ACAD in Q3 2019 and held it in 1 quarter. The position peaked at $363K in Q3 2019. 273 funds tracked by Wall St. Rank hold ACAD as of Q4 2019.

Lido Advisors reported no remaining Acadia Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Lido Advisors sold 10,100 Acadia Pharmaceuticals shares in Q4 2019, an estimated $363K.
Lido Advisors first reported a position in Acadia Pharmaceuticals in Q3 2019 and held it in 1 quarter.
Lido Advisors's Acadia Pharmaceuticals position peaked at $363K in Q3 2019.
273 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2019.

Based on Lido Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.